Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Do All Patients with Multiple Sclerosis Benefit from the Use of Contrast on Serial Follow-Up MR Imaging? A Retrospective Analysis

Do All Patients with Multiple Sclerosis Benefit from the Use of Contrast on Serial Follow-Up MR... ORIGINAL RESEARCH ADULT BRAIN Do All Patients with Multiple Sclerosis Benefit from the Use of Contrast on Serial Follow-Up MR Imaging? A Retrospective Analysis X R.R. Mattay, X K. Davtyan, X M. Bilello, and X A.C. Mamourian ABSTRACT BACKGROUND AND PURPOSE: Patients with multiple sclerosis routinely have MR imaging with contrast every 6–12 months to assess response to medication. Multiple recent studies provide evidence of tissue deposition of MR imaging contrast agents, questioning the long-termsafetyoftheseagents.Thegoalofthisretrospectiveimage-analysisstudywastodeterminewhethercontrastcouldbereserved for only those patients who show new MS lesions on follow-up examinations. MATERIALS AND METHODS: We retrospectively reviewed brain MRIs of 138 patients. To increase our sensitivity, we used a previously described computerized image-comparison software to evaluate the stability or progression of multiple sclerosis white matter lesions in noncontrast FLAIR sequences. We correlated these findings with evidence of contrast-enhancing lesions on the enhanced T1 sequence from the same scan. RESULTS: Thirty-three scans showed an increase in white matter lesion burden. Among those 33 patients, 14 examinations also demon- strated enhancing new lesions. While we found a single example of enhancement of a pre-existing white matter lesion that appeared unchanged in size, that same examination showed an overall increase in lesion burden with enhancement of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Neuroradiology American Journal of Neuroradiology

Do All Patients with Multiple Sclerosis Benefit from the Use of Contrast on Serial Follow-Up MR Imaging? A Retrospective Analysis

Loading next page...
 
/lp/american-journal-of-neuroradiology/do-all-patients-with-multiple-sclerosis-benefit-from-the-use-of-Cf2EfHogkR
Publisher
American Journal of Neuroradiology
Copyright
© 2018 by American Journal of Neuroradiology
ISSN
0195-6108
eISSN
1936-959X
DOI
10.3174/ajnr.A5828
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL RESEARCH ADULT BRAIN Do All Patients with Multiple Sclerosis Benefit from the Use of Contrast on Serial Follow-Up MR Imaging? A Retrospective Analysis X R.R. Mattay, X K. Davtyan, X M. Bilello, and X A.C. Mamourian ABSTRACT BACKGROUND AND PURPOSE: Patients with multiple sclerosis routinely have MR imaging with contrast every 6–12 months to assess response to medication. Multiple recent studies provide evidence of tissue deposition of MR imaging contrast agents, questioning the long-termsafetyoftheseagents.Thegoalofthisretrospectiveimage-analysisstudywastodeterminewhethercontrastcouldbereserved for only those patients who show new MS lesions on follow-up examinations. MATERIALS AND METHODS: We retrospectively reviewed brain MRIs of 138 patients. To increase our sensitivity, we used a previously described computerized image-comparison software to evaluate the stability or progression of multiple sclerosis white matter lesions in noncontrast FLAIR sequences. We correlated these findings with evidence of contrast-enhancing lesions on the enhanced T1 sequence from the same scan. RESULTS: Thirty-three scans showed an increase in white matter lesion burden. Among those 33 patients, 14 examinations also demon- strated enhancing new lesions. While we found a single example of enhancement of a pre-existing white matter lesion that appeared unchanged in size, that same examination showed an overall increase in lesion burden with enhancement of

Journal

American Journal of NeuroradiologyAmerican Journal of Neuroradiology

Published: Nov 1, 2018

There are no references for this article.